Investigational drug · Phase 2
MAR001
Not approved by FDA. In 3 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Hypertriglyceridemia.
Phase 2Last checked: Nov 19, 2026Latest source record: Sep 2, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
3
2 still active
All registered trials
3
Any phase or sponsor naming "MAR001"
First trial start
2023
Jul 22, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "MAR001", any sponsor or status.
Conditions studied
As listed on its trial records.
- Hypertriglyceridemia
Approved drugs for the same conditions: High triglycerides · Cardiovascular and metabolic
Largest trials
Live from ClinicalTrials.gov: studies naming "MAR001" as an intervention, largest first.
- Study of MAR001 in Adults With Elevated Triglycerides and Remnant CholesterolPivotal-lookingRecruiting
Marea TherapeuticsIndustry
NCT07028749 · 316 participants (planned) · Start Jun 30, 2025 · Primary completion Nov 2027
Drug: MAR001; Placebo · For: Hypertriglyceridemia
Sites: Anniston, Alabama; Mobile, Alabama; Little Rock, Arkansas · 55 sites in all
Marea TherapeuticsIndustry
NCT05896254 · 55 participants · Start Jul 22, 2023 · Primary completion Dec 13, 2024
Drug: MAR001; Placebo · For: Hypertriglyceridemia
Sites: Brisbane, Australia; Melbourne, Australia
- A Mechanistic Study of MAR001 in Adults With Elevated Triglycerides and Remnant CholesterolRecruiting
Marea TherapeuticsIndustry
NCT07199309 · 30 participants (planned) · Start Sep 26, 2025 · Primary completion Jul 2026
Drug: MAR001; Placebo · For: Hypertriglyceridemia
Sites: Chula Vista, California
Newest research
PubMed records naming it or its code names, newest first.
- ANGPTL4 Inhibition in Adults with Elevated Triglyceride Levels.
O'Donoghue ML, Juliano RA, Yi BA, et al. · N Engl J Med 2026
- Hypertriglyceridaemia and elevated cardiovascular risk: will ANGPTL4 inhibition address both?
Katzmann JL, Laufs U · Cardiovasc Res 2025
- Antibody-Based Therapeutics for Hypercholesterolemia.
Tomlinson B, Chan P · Biologics 2025
- An ANGPTL4 inhibitory antibody safely improves lipid profiles in non-human primates.
Cummings BB, Bouchard PR, Milton MN, et al. · EBioMedicine 2025
- Safety and efficacy of a novel ANGPTL4 inhibitory antibody for lipid lowering: results from phase 1 and phase 1b/2a clinical studies.
Cummings BB, Joing MP, Bouchard PR, et al. · Lancet 2025
Also in development for Hypertriglyceridemia
- SHR-1918Phase 37 trials
Beijing Suncadia Pharmaceuticals Co., Ltd · Homozygous Familial Hypercholesterolemia, Hyperlipidemia, Hypercholesterolemia
- DR10624Phase 35 trials
Zhejiang Doer Biologics Co., Ltd. · Severe Hypertriglyceridemia, Hypertriglyceridemia, Severe Hypertriglyceridemia (sHTG)
- RBD5044Phase 22 trials
Ribocure Pharmaceuticals AB · Dyslipidemias, Hypertriglyceridemia
- ION775Phase 21 trial
Ionis Pharmaceuticals · Hypertriglyceridemia, Severe Hypertriglyceridemia
- JMT202Phase 21 trial
Shanghai JMT-Bio Inc. · Hypertriglyceridemia
- MN-001Phase 21 trial
MediciNova · Diabetes Mellitus, Type 2, Hypertriglyceridemia, Non-Alcoholic Fatty Liver Disease
- RN0361Phase 21 trial
Ikaria Bioscience Pty Ltd · Hypertriglyceridemia, Familial Chylomicronemia Syndrome
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.